Physician profile
Eric B Harmon
NPI 1972778934
$10,075.66
in general payments reported to CMS, 2019-2025
25 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,219 · 2022: $1,523 · 2023: $2,283 · 2024: $3,431 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,012 · Consulting Fee: $1,000 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,011.92 |
| Consulting Fee | $1,000.00 |
| Education | $322.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,950.67 | 2021-2025 | |
| Janssen Biotech, INC. | $1,296.32 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $833.08 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $728.59 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $574.00 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $466.77 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $448.45 | 2021-2025 | |
| Leo Pharma INC. | $416.07 | 2021-2023 | Adbry |
| Dermavant Sciences, INC. | $413.72 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $400.72 | 2021-2025 | Siliq, Targretin |
| Sun Pharmaceutical Industries INC. | $293.45 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $245.29 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $179.61 | 2023-2025 | Zoryve |
| Organon LLC | $174.84 | 2024-2025 | Vtama |
| Genzyme Corporation | $107.38 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $105.96 | 2021-2025 | Bimzelx |
| Biofrontera INC. | $84.03 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $80.89 | 2022-2023 | Poteligeo |
| Galderma Laboratories, L.P. | $78.20 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $54.30 | 2021-2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $51.08 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $28.99 | 2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $23.00 | 2025 | Nuzyra |
| Biowound Solutions, INC. | $20.30 | 2025 | Bio-Connekt |
| Genentech USA, INC. | $19.95 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.